Month: February 2021
-
Evaluating Perioperative Chemotherapy for Pancreatic Cancer
Perioperative chemotherapy treatment did not improve overall survival for patients with resectable pancreatic cancer, according to a recent Northwestern Medicine clinical trial.
-
Celebrating 75 Years of Partnership with the VA
A model forged at Northwestern, academic affiliations with Veteran’s hospitals changed American medicine — providing care for veterans, training for future physicians and advancing scientific discovery.
-
Blocking Cell Division in Glioblastoma
Blocking the arginine methylation pathway, which helps brain tumor cells proliferate by promoting cell division, could improve cancer therapies, according to a recent study.
-
Northwestern Investigators Explore COVID-19 Treatments
Working with large, multicenter teams, Northwestern clinician-scientists have examined treatments for blood clotting in critically ill patients with COVID-19, and explored therapies that could reduce disease progression and hospitalization.
-
Tackling Inflammation to Improve Heart Attack Recovery
Inhibiting an inflammatory pathway reduced heart attack-induced damage in experimental models, according to a recent Northwestern Medicine study.
-
Physical Therapy Student Helps Save a Life
Alyssa Martinez, a second-year student in the Doctor of Physical Therapy (DPT) program, recently put her newly acquired medical skills to use to help save a man’s life.
-
Untangling Cellular Changes in Pediatric Epilepsy
For the first time, Northwestern Medicine scientists have characterized how a genetic mutation associated with pediatric epilepsy affects neuron activity.
-
Inhibiting Protein Degradation May Prevent Cocaine-Induced Reward Behaviors
Northwestern Medicine investigators have discovered that inhibiting a specific autophagy protein found in dopaminergic neurons may prevent reward-related behaviors induced by cocaine misuse.
-
Identifying Therapeutic Targets for B-cell Acute Lymphoblastic Leukemia
Northwestern Medicine investigators have identified a protein kinase called DYRK1A and its downstream substrates as potential therapeutic targets for treating pediatric patients with B-cell acute lymphoblastic leukemia.
-
Antibody Drug Improves Survival for Aggressive Breast Cancer
A new antibody drug demonstrated similar efficacy to currently available therapies to treat advanced ERBB2-positive breast cancer, according to a recent clinical trial.
